Minerva Neurosciences, Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
State of Incorporation
MA
Business Address
1500 DISTRICT AVENUE, BURLINGTON, MA, 01803
Mailing Address
1500 DISTRICT AVENUE, BURLINGTON, MA, 01803
Phone
617-600-7373
Fiscal Year End
1231
EIN
260784194
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 8-K Current report of material events | April 2, 2026 | View on SEC |
| 4 Insider stock transaction report | April 1, 2026 | View on SEC |
| 10-K Annual financial report | March 11, 2026 | View on SEC |
| 8-K Current report of material events | March 11, 2026 | View on SEC |
| S-3 Shelf registration for future offerings | March 11, 2026 | View on SEC |
| SCHEDULE 13G Passive beneficial ownership (>5%) | February 20, 2026 | View on SEC |
| SCHEDULE 13G Passive beneficial ownership (>5%) | February 17, 2026 | View on SEC |
| SCHEDULE 13G Passive beneficial ownership (>5%) | February 17, 2026 | View on SEC |
| SCHEDULE 13G Passive beneficial ownership (>5%) | February 12, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 5, 2026 | View on SEC |
Annual Reports
10-K
March 11, 2026
- Roluperidone advancing towards FDA New Drug Application (NDA) submission, a critical milestone.
- Successfully completed a private placement in October and December 2025, raising $30.0 million.
Material Events
8-K
Leadership Change
April 2, 2026
High Impact
- Strategic pivot toward aggressive legal and regulatory advocacy for roluperidone
- Appointment of Jim O’Connor as CBO/General Counsel to lead FDA dispute resolution
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.